Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules

Bahareh Sayyar, Megan Dodd, Leah Marquez-Curtis, Anna Janowska-Wieczorek, Gonzalo Hortelano

    Research output: Contribution to journalArticle

    9 Citations (Scopus)

    Abstract

    The success of cell microencapsulation technology in tissue engineering and protein delivery applications depends on the viability and functionality of the encapsulated cells, which in turn are dependent upon cell/matrix interactions. In this work, we compared the viability of cord blood-derived mesenchymal stromal cells (CB MSCs), engineered to secrete factor IX (FIX) for hemophilia treatment, and encapsulated in arginine-glycine-aspartate (RGD)-alginate versus fibrinogen-alginate microcapsules. We evaluated the effect of the biomimetic matrix on cell attachment, proliferation, and secretion of FIX. Compared with nonsupplemented alginate matrix, RGD-alginate significantly enhanced the viability of the encapsulated MSCs. Further, cells in RGD-alginate displayed distinct attachment morphology, thus suggesting that RGD-alginate can potentially be used for the encapsulation of MSCs in tissue engineering applications that require enhanced cell attachment and viability. However, our data also showed that RGD-alginate microcapsules, in contrast to fibrinogen-alginate microcapsules, did not significantly improve cell proliferation of or FIX secretion by encapsulated MSCs. Our findings suggest that evidence of cell attachment alone may not accurately predict the functionality of cells in biomimetic microcapsules.

    Original languageEnglish
    Pages (from-to)102-109
    Number of pages8
    JournalArtificial Cells, Nanomedicine and Biotechnology
    Volume42
    Issue number2
    DOIs
    Publication statusPublished - 2014

    Fingerprint

    Factor IX
    Alginate
    Mesenchymal Stromal Cells
    Cell Communication
    Fibrinogen
    Capsules
    Biomimetics
    Tissue Engineering
    Tissue engineering
    Cell Proliferation
    Microencapsulation
    Drug Compounding
    Arginine
    alginic acid
    Cell proliferation
    Hemophilia A
    Fetal Blood
    Encapsulation
    Glycine
    Amino acids

    Keywords

    • Alginate
    • Cell microencapsulation
    • Fibrinogen
    • FIX
    • Mesenchymal stromal cell
    • RGD

    ASJC Scopus subject areas

    • Biotechnology
    • Biomedical Engineering
    • Medicine (miscellaneous)
    • Pharmaceutical Science
    • Medicine(all)

    Cite this

    Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules. / Sayyar, Bahareh; Dodd, Megan; Marquez-Curtis, Leah; Janowska-Wieczorek, Anna; Hortelano, Gonzalo.

    In: Artificial Cells, Nanomedicine and Biotechnology, Vol. 42, No. 2, 2014, p. 102-109.

    Research output: Contribution to journalArticle

    @article{2f8d8a2a96224f2fb6a07b007b4d73c9,
    title = "Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules",
    abstract = "The success of cell microencapsulation technology in tissue engineering and protein delivery applications depends on the viability and functionality of the encapsulated cells, which in turn are dependent upon cell/matrix interactions. In this work, we compared the viability of cord blood-derived mesenchymal stromal cells (CB MSCs), engineered to secrete factor IX (FIX) for hemophilia treatment, and encapsulated in arginine-glycine-aspartate (RGD)-alginate versus fibrinogen-alginate microcapsules. We evaluated the effect of the biomimetic matrix on cell attachment, proliferation, and secretion of FIX. Compared with nonsupplemented alginate matrix, RGD-alginate significantly enhanced the viability of the encapsulated MSCs. Further, cells in RGD-alginate displayed distinct attachment morphology, thus suggesting that RGD-alginate can potentially be used for the encapsulation of MSCs in tissue engineering applications that require enhanced cell attachment and viability. However, our data also showed that RGD-alginate microcapsules, in contrast to fibrinogen-alginate microcapsules, did not significantly improve cell proliferation of or FIX secretion by encapsulated MSCs. Our findings suggest that evidence of cell attachment alone may not accurately predict the functionality of cells in biomimetic microcapsules.",
    keywords = "Alginate, Cell microencapsulation, Fibrinogen, FIX, Mesenchymal stromal cell, RGD",
    author = "Bahareh Sayyar and Megan Dodd and Leah Marquez-Curtis and Anna Janowska-Wieczorek and Gonzalo Hortelano",
    year = "2014",
    doi = "10.3109/21691401.2013.794354",
    language = "English",
    volume = "42",
    pages = "102--109",
    journal = "Artificial Cells, Nanomedicine and Biotechnology",
    issn = "2169-1401",
    publisher = "Informa Healthcare",
    number = "2",

    }

    TY - JOUR

    T1 - Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules

    AU - Sayyar, Bahareh

    AU - Dodd, Megan

    AU - Marquez-Curtis, Leah

    AU - Janowska-Wieczorek, Anna

    AU - Hortelano, Gonzalo

    PY - 2014

    Y1 - 2014

    N2 - The success of cell microencapsulation technology in tissue engineering and protein delivery applications depends on the viability and functionality of the encapsulated cells, which in turn are dependent upon cell/matrix interactions. In this work, we compared the viability of cord blood-derived mesenchymal stromal cells (CB MSCs), engineered to secrete factor IX (FIX) for hemophilia treatment, and encapsulated in arginine-glycine-aspartate (RGD)-alginate versus fibrinogen-alginate microcapsules. We evaluated the effect of the biomimetic matrix on cell attachment, proliferation, and secretion of FIX. Compared with nonsupplemented alginate matrix, RGD-alginate significantly enhanced the viability of the encapsulated MSCs. Further, cells in RGD-alginate displayed distinct attachment morphology, thus suggesting that RGD-alginate can potentially be used for the encapsulation of MSCs in tissue engineering applications that require enhanced cell attachment and viability. However, our data also showed that RGD-alginate microcapsules, in contrast to fibrinogen-alginate microcapsules, did not significantly improve cell proliferation of or FIX secretion by encapsulated MSCs. Our findings suggest that evidence of cell attachment alone may not accurately predict the functionality of cells in biomimetic microcapsules.

    AB - The success of cell microencapsulation technology in tissue engineering and protein delivery applications depends on the viability and functionality of the encapsulated cells, which in turn are dependent upon cell/matrix interactions. In this work, we compared the viability of cord blood-derived mesenchymal stromal cells (CB MSCs), engineered to secrete factor IX (FIX) for hemophilia treatment, and encapsulated in arginine-glycine-aspartate (RGD)-alginate versus fibrinogen-alginate microcapsules. We evaluated the effect of the biomimetic matrix on cell attachment, proliferation, and secretion of FIX. Compared with nonsupplemented alginate matrix, RGD-alginate significantly enhanced the viability of the encapsulated MSCs. Further, cells in RGD-alginate displayed distinct attachment morphology, thus suggesting that RGD-alginate can potentially be used for the encapsulation of MSCs in tissue engineering applications that require enhanced cell attachment and viability. However, our data also showed that RGD-alginate microcapsules, in contrast to fibrinogen-alginate microcapsules, did not significantly improve cell proliferation of or FIX secretion by encapsulated MSCs. Our findings suggest that evidence of cell attachment alone may not accurately predict the functionality of cells in biomimetic microcapsules.

    KW - Alginate

    KW - Cell microencapsulation

    KW - Fibrinogen

    KW - FIX

    KW - Mesenchymal stromal cell

    KW - RGD

    UR - http://www.scopus.com/inward/record.url?scp=84896117256&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84896117256&partnerID=8YFLogxK

    U2 - 10.3109/21691401.2013.794354

    DO - 10.3109/21691401.2013.794354

    M3 - Article

    VL - 42

    SP - 102

    EP - 109

    JO - Artificial Cells, Nanomedicine and Biotechnology

    JF - Artificial Cells, Nanomedicine and Biotechnology

    SN - 2169-1401

    IS - 2

    ER -